Published in Transl Psychiatry on October 18, 2016
New drugs in psychiatry: focus on new pharmacological targets. F1000Res (2017) 0.75
Improved Social Interaction, Recognition and Working Memory with Cannabidiol Treatment in a Prenatal Infection (poly I:C) Rat Model. Neuropsychopharmacology (2017) 0.75
Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol (1973) 47.81
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol (2007) 3.16
Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet (2003) 3.08
High-potency cannabis and the risk of psychosis. Br J Psychiatry (2009) 2.41
Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci U S A (1975) 2.16
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry (2012) 1.77
Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry (2012) 1.73
Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry (2008) 1.49
All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors. CNS Neurosci Ther (2011) 1.30
Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis. Neuropharmacology (2008) 1.20
Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci (2012) 1.15
Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci (1998) 1.14
The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form. Endocrinology (1985) 1.10
Looking for the role of cannabinoid receptor heteromers in striatal function. Neuropharmacology (2008) 1.06
Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacology (2006) 1.00
Antiparkinson therapeutic potencies correlate with their affinities at dopamine D2(High) receptors. Synapse (2007) 0.95
Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology (Berl) (1991) 0.95
Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil. Synapse (2009) 0.94
Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Eur J Pharmacol (2005) 0.93
Dopamine receptor parameters detected by [3H]spiperone depend on tissue concentration: analysis and examples. J Neurochem (1984) 0.93
L-DOPA-treatment in primates disrupts the expression of A(2A) adenosine-CB(1) cannabinoid-D(2) dopamine receptor heteromers in the caudate nucleus. Neuropharmacology (2013) 0.91
Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia. J Psychopharmacol (2015) 0.89
Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum. Life Sci (2004) 0.84
Dopaminergic inhibition of adenylate cyclase correlates with high affinity agonist binding to anterior pituitary D2 dopamine receptors. Mol Cell Endocrinol (1984) 0.84
Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol. Schizophr Res (2015) 0.83
Dopamine D2(High) receptors moderately elevated by bifeprunox and aripiprazole. Synapse (2008) 0.81